US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

10.42

+0.27002.66%

Post-market: 10.420.00000.00%16:05 EDT

Volume:69.41K

Turnover:730.85K

Market Cap:269.95M

PE:-2.32

High:11.31

Open:10.26

Low:10.00

Close:10.15

Loading ...

Overview Company News Filings

Cartesian Therapeutics Is Maintained at Buy by Needham

Buy Rating for Cartesian Therapeutics: Promising Clinical Progress and Stable Financial Outlook

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

Cartesian Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Cartesian Therapeutics Q1 EPS $(0.68) Beats $(0.71) Estimate, Sales $1.10M Beat $785.71K Estimate

Cartesian Therapeutics Net Loss $17.7 Mln, or $0.68 Net Loss per Share (Basic) in Q1

THOMSON REUTERS

Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 in Mg Expected 2Q25 - SEC Filing

THOMSON REUTERS

Calendar of U.S. Earnings Expected in the Week Ahead

Cartesian Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics management to meet with BTIG

Major Investment Alert: Director Buys Big in Cartesian Therapeutics!

Buy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile

Cartesian Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Mizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)

Cartesian Therapeutics Shares Rise on Positive Phase 2b Trial Results

BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics announces employment inducement grants

Cartesian Therapeutics Announces New Employment Inducement Grants

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RNAC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","market":"US","secType":"STK","nameCN":"Cartesian Therapeutics","latestPrice":10.42,"timestamp":1746734400000,"preClose":10.15,"halted":0,"volume":69407,"hourTrading":{"tag":"盘后","latestPrice":10.42,"preClose":10.42,"latestTime":"16:05 EDT","volume":50,"amount":521,"timestamp":1746734705701},"delay":0,"floatShares":9302905,"shares":25907101,"eps":-4.48613,"marketStatus":"Post-Mkt","change":0.27,"latestTime":"05-08 17:23:30 EDT","open":10.26,"high":11.31,"low":10,"amount":730847.9903,"amplitude":0.129064,"askPrice":11.31,"askSize":3,"bidPrice":10.02,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.48613,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746748800000},"marketStatusCode":4,"adr":0,"listingDate":1466568000000,"exchange":"NASDAQ","adjPreClose":10.15,"preHourTrading":{"tag":"盘前","latestPrice":10.5,"preClose":10.15,"latestTime":"08:00 EDT","volume":100,"amount":1050,"timestamp":1746705600679},"postHourTrading":{"tag":"盘后","latestPrice":10.42,"preClose":10.42,"latestTime":"16:05 EDT","volume":50,"amount":521,"timestamp":1746734705701},"volumeRatio":0.933826,"impliedVol":0.7622,"impliedVolPercentile":0.4375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","floatShares":9302905,"roa":"-6.00%","roe":"-7029.26%","lyrEps":-4.481379,"volumeRatio":0.933826,"shares":25907101,"dividePrice":0,"high":11.31,"amplitude":0.129064,"preClose":10.15,"low":10,"week52Low":8.85,"pbRate":"-39.69","psRate":"6.94","week52High":41.87,"institutionHeld":0,"latestPrice":10.42,"committee":0.941748,"eps":-4.48613,"divideRate":0,"volume":69407,"delay":0,"ttmEps":-4.48613,"open":10.26,"prevYearClose":17.91,"prevWeekClose":12.7,"prevMonthClose":12,"prevQuarterClose":13.18,"fiveDayClose":12.27,"twentyDayClose":11.36,"sixtyDayClose":18.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNAC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534016873","title":"Cartesian Therapeutics Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2534016873","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534016873?lang=en_us&edition=fundamental","pubTime":"2025-05-09 03:08","pubTimestamp":1746731280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2025 15:08 ET (19:08 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2534592141","title":"Buy Rating for Cartesian Therapeutics: Promising Clinical Progress and Stable Financial Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2534592141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534592141?lang=en_us&edition=fundamental","pubTime":"2025-05-09 00:36","pubTimestamp":1746722163,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today and set a price target of $40.00. Gil Blu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cartesian-therapeutics-promising-clinical-progress-and-stable-financial-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cartesian-therapeutics-promising-clinical-progress-and-stable-financial-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","PRGS"],"gpt_icon":0},{"id":"2533933132","title":"Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533933132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533933132?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:40","pubTimestamp":1746715217,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Harrow Health (HROW – Research Report) and Cartesian...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-harrow-health-hrow-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-harrow-health-hrow-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HROW","BK4557","HCSG","RNAC","BK4137","BK4007"],"gpt_icon":0},{"id":"2533313556","title":"Cartesian Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2533313556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533313556?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:32","pubTimestamp":1746711134,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryCartesian Therapeutics Inc RNAC.OQ reported a quarterly adjusted loss of 68 cents per share for the quarter ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG1YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2533387911","title":"Cartesian Therapeutics Q1 EPS $(0.68) Beats $(0.71) Estimate, Sales $1.10M Beat $785.71K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533387911","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533387911?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:15","pubTimestamp":1746710101,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.71) by 4.23 percent. This is a 93.52 percent increase over losses of $(10.50) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45285593/cartesian-therapeutics-q1-eps-0-68-beats-0-71-estimate-sales-1-10m-beat-785-71k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2533736185","title":"Cartesian Therapeutics Net Loss $17.7 Mln, or $0.68 Net Loss per Share (Basic) in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2533736185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533736185?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:29","pubTimestamp":1746703747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG36G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2533072185","title":"Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 in Mg Expected 2Q25 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533072185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533072185?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:29","pubTimestamp":1746703747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG36G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2533609942","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2533609942","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533609942?lang=en_us&edition=fundamental","pubTime":"2025-05-07 18:00","pubTimestamp":1746612000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A-Mark Prcs Mtls                                 3Q       .55    4:05 PM. ·Alpha and Omega                                  3Q      (.17)   4:01 PM. ·Ares Cmm. Rl Est                                 1Q       .00    6:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTRI","GOLF","BLZE","BTMD","DFH","BLBD","BWA","AMRK","CSGS","AOSL","BSY","BYND","ASLE","AVA","DAY","CLRB","AIRG","AVDX","BBSI","BRKR","BLTE","BAND","APA","TKNO","ADNT","CPK","CVNA","BDTX","RNAC","DHX","DIN","CF","CIVI","TECH","ACRE","CING","CPRX","AXON","BLMN","BV","AVDL","CNTX","CRNC","ALTG","CMTG","CXW","CLF","EPC","CW"],"gpt_icon":1},{"id":"2532083846","title":"Cartesian Therapeutics Inc  expected to post a loss of 71 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2532083846","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532083846?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:05","pubTimestamp":1746191106,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics Inc  expected to post a loss of71cents a share - Earnings Preview Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to show a fall in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nL8N3RA1TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2532084326","title":"Cartesian Therapeutics Announces New Employment Inducement Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2532084326","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532084326?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:05","pubTimestamp":1746183900,"startTime":"0","endTime":"0","summary":"FREDERICK, Md., May 02, 2025  -- Cartesian Therapeutics, Inc.  , a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2025, the Company issued to these employees options to purchase an aggregate of 27,700 shares of the Company’s common stock with an exercise price of $12.27, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on May 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on May 1, 2029. The options have a ten-year term. The options were granted under Rule 5635 of the Nasdaq Listing Rules as an inducement material to the employees’ entr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cartesian-therapeutics-announces-employment-inducement-110500914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2530963963","title":"Cartesian Therapeutics management to meet with BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2530963963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530963963?lang=en_us&edition=fundamental","pubTime":"2025-04-25 01:06","pubTimestamp":1745514415,"startTime":"0","endTime":"0","summary":"Meeting to be held in Austin and Dallas on May 1 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-management-to-meet-with-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-management-to-meet-with-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2526462009","title":"Major Investment Alert: Director Buys Big in Cartesian Therapeutics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2526462009","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526462009?lang=en_us&edition=fundamental","pubTime":"2025-04-12 10:02","pubTimestamp":1744423339,"startTime":"0","endTime":"0","summary":"New insider activity at Cartesian Therapeutics ( ($RNAC) ) has taken place on April 12, 2025. Director Timothy A. Springer has made a significant i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investment-alert-director-buys-big-in-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investment-alert-director-buys-big-in-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2526588372","title":"Buy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2526588372","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526588372?lang=en_us&edition=fundamental","pubTime":"2025-04-10 14:26","pubTimestamp":1744266376,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating yesterday. Thomas Smith has given his ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-cartesian-therapeutics-due-to-promising-phase-2b-trial-results-and-strong-safety-profile?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-cartesian-therapeutics-due-to-promising-phase-2b-trial-results-and-strong-safety-profile?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2526819368","title":"Cartesian Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2526819368","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526819368?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:48","pubTimestamp":1744199280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 07:48 ET (11:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2526980851","title":"Mizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526980851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526980851?lang=en_us&edition=fundamental","pubTime":"2025-04-09 10:35","pubTimestamp":1744166106,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Uy Ear from Mizuho Securities maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-cartesian-therapeutics-rnac?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","MFG"],"gpt_icon":0},{"id":"2525815476","title":"Cartesian Therapeutics Shares Rise on Positive Phase 2b Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2525815476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525815476?lang=en_us&edition=fundamental","pubTime":"2025-04-08 22:11","pubTimestamp":1744121460,"startTime":"0","endTime":"0","summary":"Shares of Cartesian Therapeutics climbed after the company announced positive results in a phase 2b trial of its lead cell-therapy candidate.The stock was up 8.3% to $15.60 in morning trading Tuesday. Shares are off 39% year to date.The Frederick, Md., clinical-stage maker of therapies for autoimmune diseases said Tuesday that a long-term follow-up assessment of its Descartes-08 treatment showed deep and sustained benefits in participants with generalized myasthenia gravis, or MG. Cartesian said participants at their 12-month follow-up assessment showed an average 4.8-point reduction in the score for MG activities of daily living, or MG-ADL, after a single six-week course of treatment.Cartesian added that the deepest and most-compelling sustained responses were seen in participants without prior exposure to biologic therapies, showing an average 7.1-point reduction in their MG-ADL, and with 57% of these patients maintaining minimum symptom expression at the 12-month follow-up.\"The data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2525898674","title":"BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2525898674","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525898674?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:04","pubTimestamp":1744110272,"startTime":"0","endTime":"0","summary":"BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis TrialApril 8 (Reuters) - Cart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM057:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2525893441","title":"Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2525893441","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525893441?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:00","pubTimestamp":1744110000,"startTime":"0","endTime":"0","summary":"After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12. Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12. Safety profile consistent with previously reported data and continues to support outpatient administration. In the Phase 2b double-blind, placebo-controlled, crossover trial, a total of 36 heavily pretreated, highly symptomatic participants with MG were randomized 1:1 to receive either Descartes-08 or placebo administered as six weekly outpatient infusions without preconditioning chemotherapy. As previously announced, the trial met its primary endpoint and demonstrated a safety profile supporting outpatient adminis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cartesian-therapeutics-descartes-08-observed-110000924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","CRS","IE00B7SZL793.SGD","LU2065731478.USD","BK4023","BK4006","BK4139","MGC","MG","BK4123","DSGX","IE00B19Z4B17.USD","IE0031619046.USD","RNAC","IE0009354923.USD"],"gpt_icon":0},{"id":"2524461325","title":"Cartesian Therapeutics announces employment inducement grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2524461325","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524461325?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:17","pubTimestamp":1743592623,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC) announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these empl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grants-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grants-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2524693644","title":"Cartesian Therapeutics Announces New Employment Inducement Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2524693644","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524693644?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:05","pubTimestamp":1743591900,"startTime":"0","endTime":"0","summary":"FREDERICK, Md., April  02, 2025  (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/02/3054129/0/en/Cartesian-Therapeutics-Announces-New-Employment-Inducement-Grants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNAC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"RNAC","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"pre","actualEps":-2.4},{"market":"US","date":"2024-11-07","symbol":"RNAC","fiscalQuarterEnding":"2024/09","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2024-08-08","symbol":"RNAC","fiscalQuarterEnding":"2024/06","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":0.54},{"market":"US","date":"2024-05-08","symbol":"RNAC","fiscalQuarterEnding":"2024/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-1.97},{"market":"US","date":"2024-04-05","symbol":"RNAC","defaultRemindTime":1712323800000,"type":"split","dateTimestamp":1712289600000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNAC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1734667200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNAC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNAC","date":"2025-05-07","current":-3.536863,"percent":0.175676,"low":-14.109752,"twenty":-3.070355,"median":-1.954681,"eighty":-1.384729,"high":-0.322359,"avg":-2.834343,"sd":2.976114,"marketCap":273838057},"quantilePoints":[{"date":"2024-02-09","current":-12.195228,"twenty":-12.293822,"median":-12.139657,"eighty":-11.530164,"marketCap":110159496},{"date":"2024-02-16","current":-13.543282,"twenty":-12.82193,"median":-12.371802,"eighty":-12.018117,"marketCap":122336468},{"date":"2024-02-23","current":-12.9069,"twenty":-13.170416,"median":-12.72226,"eighty":-12.169773,"marketCap":116588031},{"date":"2024-03-01","current":-13.113052,"twenty":-13.187625,"median":-12.9069,"eighty":-12.193077,"marketCap":118450201},{"date":"2024-03-08","current":-0.474472,"twenty":-13.096919,"median":-12.72226,"eighty":-12.104521,"marketCap":104246325},{"date":"2024-03-15","current":-0.394571,"twenty":-13.085087,"median":-12.369113,"eighty":-0.499332,"marketCap":86691095},{"date":"2024-03-22","current":-0.518772,"twenty":-13.077916,"median":-12.18985,"eighty":-0.473381,"marketCap":113979437},{"date":"2024-03-28","current":-0.486782,"twenty":-13.018401,"median":-12.095738,"eighty":-0.472836,"marketCap":106950867},{"date":"2024-04-05","current":-0.371573,"twenty":-12.924109,"median":-11.522994,"eighty":-0.462369,"marketCap":81638284},{"date":"2024-04-12","current":-1.459867,"twenty":-12.9069,"median":-1.226402,"eighty":-0.444134,"marketCap":320747357},{"date":"2024-04-19","current":-1.398365,"twenty":-12.846668,"median":-1.459867,"eighty":-0.462369,"marketCap":307234719},{"date":"2024-04-26","current":-1.691309,"twenty":-12.729072,"median":-1.487381,"eighty":-0.467868,"marketCap":371597548},{"date":"2024-05-03","current":-1.978779,"twenty":-12.63227,"median":-1.536745,"eighty":-0.471303,"marketCap":434757574},{"date":"2024-05-10","current":-1.526348,"twenty":-12.47667,"median":-1.594687,"eighty":-0.472836,"marketCap":389021718},{"date":"2024-05-17","current":-1.839158,"twenty":-12.299559,"median":-1.62026,"eighty":-0.47633,"marketCap":468748036},{"date":"2024-05-24","current":-1.777713,"twenty":-12.193077,"median":-1.671483,"eighty":-0.482182,"marketCap":453087509},{"date":"2024-05-31","current":-2.195259,"twenty":-12.18985,"median":-1.697348,"eighty":-0.489671,"marketCap":559507906},{"date":"2024-06-07","current":-2.422885,"twenty":-12.179811,"median":-1.717665,"eighty":-0.504164,"marketCap":617523039},{"date":"2024-06-14","current":-2.045138,"twenty":-12.139657,"median":-1.777713,"eighty":-0.515905,"marketCap":521246392},{"date":"2024-06-21","current":-1.598266,"twenty":-12.069386,"median":-1.728138,"eighty":-0.518199,"marketCap":407351653},{"date":"2024-06-28","current":-1.991374,"twenty":-11.947846,"median":-1.777713,"eighty":-0.520305,"marketCap":507543431},{"date":"2024-07-05","current":-1.23169,"twenty":-11.531957,"median":-1.728138,"eighty":-0.526438,"marketCap":313922113},{"date":"2024-07-12","current":-1.241477,"twenty":-11.522994,"median":-1.709478,"eighty":-0.530124,"marketCap":316416386},{"date":"2024-07-15","current":-1.240079,"twenty":-9.729226,"median":-1.703386,"eighty":-0.53751,"marketCap":316060062},{"date":"2024-08-02","current":-1.081399,"twenty":-7.935458,"median":-1.699966,"eighty":-0.544895,"marketCap":275617201},{"date":"2024-08-09","current":-1.198323,"twenty":-2.548847,"median":-1.676743,"eighty":-0.772791,"marketCap":275192581},{"date":"2024-08-16","current":-1.345437,"twenty":-2.529995,"median":-1.625846,"eighty":-1.101689,"marketCap":308976908},{"date":"2024-08-23","current":-1.244878,"twenty":-2.507232,"median":-1.598266,"eighty":-1.148418,"marketCap":285883824},{"date":"2024-08-30","current":-1.388267,"twenty":-2.46827,"median":-1.531547,"eighty":-1.172903,"marketCap":318812851},{"date":"2024-09-06","current":-1.307262,"twenty":-2.424002,"median":-1.519153,"eighty":-1.173531,"marketCap":300210089},{"date":"2024-09-13","current":-1.496275,"twenty":-2.390626,"median":-1.497092,"eighty":-1.177113,"marketCap":343616533},{"date":"2024-09-20","current":-1.540036,"twenty":-2.248325,"median":-1.497406,"eighty":-1.182548,"marketCap":353666301},{"date":"2024-09-27","current":-1.616387,"twenty":-2.173184,"median":-1.49772,"eighty":-1.183457,"marketCap":371199939},{"date":"2024-10-04","current":-2.374287,"twenty":-2.173184,"median":-1.519153,"eighty":-1.187433,"marketCap":545250240},{"date":"2024-10-11","current":-2.176603,"twenty":-2.352646,"median":-1.530726,"eighty":-1.193387,"marketCap":499852543},{"date":"2024-10-18","current":-2.257757,"twenty":-2.310612,"median":-1.544226,"eighty":-1.200277,"marketCap":518489492},{"date":"2024-10-25","current":-2.299664,"twenty":-2.339564,"median":-1.569114,"eighty":-1.208188,"marketCap":528113202},{"date":"2024-10-31","current":-2.199769,"twenty":-2.325678,"median":-1.616387,"eighty":-1.208566,"marketCap":505172538},{"date":"2024-11-08","current":-2.028231,"twenty":-2.320475,"median":-1.625846,"eighty":-1.217877,"marketCap":496569789},{"date":"2024-11-15","current":-1.766791,"twenty":-2.31186,"median":-1.676743,"eighty":-1.221601,"marketCap":432561563},{"date":"2024-11-22","current":-1.725268,"twenty":-2.307988,"median":-1.693927,"eighty":-1.221601,"marketCap":422395604},{"date":"2024-11-29","current":-1.954681,"twenty":-2.306323,"median":-1.709478,"eighty":-1.229672,"marketCap":478562529},{"date":"2024-12-06","current":-2.388593,"twenty":-2.306323,"median":-1.725268,"eighty":-1.23169,"marketCap":584796802},{"date":"2024-12-13","current":-2.088591,"twenty":-2.321516,"median":-1.757967,"eighty":-1.238401,"marketCap":511347747},{"date":"2024-12-20","current":-2.024787,"twenty":-2.313583,"median":-1.76875,"eighty":-1.241197,"marketCap":495726646},{"date":"2024-12-27","current":-2.088883,"twenty":-2.309537,"median":-1.777713,"eighty":-1.243092,"marketCap":511419083},{"date":"2025-01-03","current":-1.778913,"twenty":-2.307156,"median":-1.777862,"eighty":-1.244452,"marketCap":435529430},{"date":"2025-01-10","current":-1.777862,"twenty":-2.305849,"median":-1.777862,"eighty":-1.244878,"marketCap":435272177},{"date":"2025-01-17","current":-1.989062,"twenty":-2.304427,"median":-1.779554,"eighty":-1.246554,"marketCap":486980042},{"date":"2025-01-24","current":-2.040548,"twenty":-2.299664,"median":-1.784789,"eighty":-1.253258,"marketCap":499585442},{"date":"2025-01-31","current":-2.036345,"twenty":-2.283748,"median":-1.80308,"eighty":-1.272811,"marketCap":498556430},{"date":"2025-02-07","current":-1.976453,"twenty":-2.276485,"median":-1.8278,"eighty":-1.28026,"marketCap":483893005},{"date":"2025-02-14","current":-1.999569,"twenty":-2.273364,"median":-1.845442,"eighty":-1.299813,"marketCap":489552573},{"date":"2025-02-21","current":-2.060513,"twenty":-2.263946,"median":-1.859179,"eighty":-1.303538,"marketCap":504473250},{"date":"2025-02-28","current":-1.892393,"twenty":-2.258524,"median":-1.87682,"eighty":-1.306703,"marketCap":463312761},{"date":"2025-03-07","current":-1.875581,"twenty":-2.211367,"median":-1.875581,"eighty":-1.307262,"marketCap":459196712},{"date":"2025-03-14","current":-5.557927,"twenty":-2.211367,"median":-1.881886,"eighty":-1.317995,"marketCap":430316947},{"date":"2025-03-21","current":-5.33039,"twenty":-2.277938,"median":-1.88594,"eighty":-1.323353,"marketCap":412700118},{"date":"2025-03-28","current":-4.805047,"twenty":-2.306323,"median":-1.893969,"eighty":-1.325512,"marketCap":372025970},{"date":"2025-04-04","current":-4.129128,"twenty":-2.32984,"median":-1.905491,"eighty":-1.337057,"marketCap":319693626},{"date":"2025-04-11","current":-3.466594,"twenty":-2.375387,"median":-1.926854,"eighty":-1.34432,"marketCap":268397566},{"date":"2025-04-17","current":-3.536863,"twenty":-2.423443,"median":-1.931271,"eighty":-1.357169,"marketCap":273838057},{"date":"2025-04-25","current":-4.03209,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"marketCap":312180567},{"date":"2025-05-02","current":-4.105705,"twenty":-2.552358,"median":-1.945456,"eighty":-1.384171,"marketCap":317880129},{"date":"2025-05-07","current":-3.536863,"twenty":-3.070355,"median":-1.954681,"eighty":-1.384729,"marketCap":273838057}],"updateTime":1746701097044}}}